The estimated Net Worth of Associates Llc Brightstar is at least $505 Миллион dollars as of 24 January 2023. Associates Brightstar owns over 1,666,666 units of Deciphera Pharmaceuticals Inc stock worth over $504,583,978 and over the last 7 years Associates sold DCPH stock worth over $0.
Associates has made over 2 trades of the Deciphera Pharmaceuticals Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Associates bought 1,666,666 units of DCPH stock worth $29,999,988 on 24 January 2023.
The largest trade Associates's ever made was buying 1,666,666 units of Deciphera Pharmaceuticals Inc stock on 24 January 2023 worth over $29,999,988. On average, Associates trades about 524,274 units every 45 days since 2017. As of 24 January 2023 Associates still owns at least 19,718,014 units of Deciphera Pharmaceuticals Inc stock.
You can see the complete history of Associates Brightstar stock trades at the bottom of the page.
Associates's mailing address filed with the SEC is 1020 Central St #300, Kansas City, MO 64105, USA.
Over the last 7 years, insiders at Deciphera Pharmaceuticals Inc have traded over $25,274,872 worth of Deciphera Pharmaceuticals Inc stock and bought 3,916,644 units worth $57,831,028 . The most active insiders traders include Liam Ratcliffe, Associates Llc Brightstar и Ron Squarer. On average, Deciphera Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $1,218,775. The most recent stock trade was executed by Thomas Patrick Kelly on 15 February 2024, trading 3,010 units of DCPH stock currently worth $47,016.
deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.
Deciphera Pharmaceuticals Inc executives and other stock owners filed with the SEC include: